Table 1 Demographics, clinical and epidemiological characteristics of included patients

Patients

157 (100%)

47 (29.94%)

57 (36.31%)

20 (12.74%)

17 (10.83%)

16 (10.19%)

 Male

119 (75.8%)

37 (78.72%)

42 (73.68%)

14 (70%)

11 (64.7%)

15 (93.75%)

 Female

38 (24.2%)

10 (21.28%)

15 (26.32%)

6 (30%)

6 (35.29%)

1 (6.25%)

Age at initial diagnosis (mean, std, years)

64.39 (+/- 10.71)

61.74 (+/- 9.24)

61.6 (+/- 9.49)

71.6 (+/- 12.14)

70.6 (+/- 10.86)

63.06 (+/- 11.86)

Tumor localization

 Outer nose and nasal cavities

8 (5.09%)

2 (4.25%)

2 (3.51%)

2 (10%)

0 (0%)

2 (12.5%)

 Oral cavity

36 (22.92%)

18 (38.3%)

5 (8.77%)

4 (20%)

5 (29.41%)

4 (25%)

 Tounge margin

1 (0.64%)

0 (0%)

0 (0%)

0 (0%)

1 (5.88%)

0 (0%)

 Oropharynx

51 (32.48%)

9 (19.15%)

23 (40.35%)

7 (35%)

7 (41.18%)

5 (31.25%)

 Hypopharynx

14 (8.92%)

1 (2.13%)

8 (14.04%)

3 (15%)

0 (0%)

2 (12.5%)

 Larynx

47 (29.94%)

17 (36.17%)

19 (33.33%)

4 (20%)

4 (23.53%)

3 (18.75%)

Carcinogen exposure

52 [105] (33.12%)

15 [32] (31.91%)

19 [38] (33.33%)

10 [10] (50%)

4 [13] (23.53%)

4 [12] (25%)

 Alcohol

3 [105] (5.77%)

1 [32] (6.67%)

1 [38] (5.26%)

0 [10] (0%)

1 [13] (25%)

0 [12] (0%)

 Smoking

26 [105] (50%)

7 [32] (46.67%)

9 [38] (47.37%)

6 [10] (60%)

2 [13] (50%)

2 [12] (50%)

 Alcohol and smoking

23 [105] (44.23%)

7 [32] (46.67%)

9 [38] (47.36%)

4 [10] (40%)

1 [13] (50%)

2 [12] (50%)

Immunohistochemistry at initial diagnosis^ab

 CK 5/6^b and p63^b tested

99 [58] (63.06%)

30 [17] (63.83%)

39 [18] (68.42%)

14 [6] (70%)

11 [6] (64.71%)

5 [11] (31.25%)

  CK 5/6^b and p63^b positive

84 [58] (84.85%)

26 [17] (86.67%)

31 [18] (79.5%)

13 [6] (92.9%)

10 [6] (90.9%)

4 [11] (80%)

  CK 5/6^b and p63^b negative

15 [58] (15.15%)

4 [17] (13.33%)

8 [18] (20.5%)

1 [6] (7.1%)

1 [6] (9.1%)

1 [11] (20%)

 p16^b tested

99 [58] (63.06%)

30 [17] (63.83%)

39 [18] (68.42%)

14 [6] (70%)

11 [6] (64.71%)

5 [11] (31.25%)

  p16^b positive

27 [58] (27.27%)

6 [17] (20%)

13 [18] (33.3%)

3 [6] (21.43%)

2 [6] (18.2%)

3 [11] (60%)

  p16^b negative

72 [58] (72.73%)

24 [17] (80%)

26 [18] (66.7%)

11 [6] (78.57%)

9 [6] (81.8%)

2 [11] (40%)

Grading^c

 CIS (carcinoma in situ)

6 [1] (3.85%)

0 (0%)

3 [1] (5.36%)

1 (5%)

0 (0%)

2 (12.5%)

 G1

5 [1] (3.21%)

3 (6.4%)

0 [1] (0%)

1 (5%)

1 (5.88%)

0 (0%)

 G2

118 [1] (75.64%)

37 (78.2%)

41 [1] (73.21%)

16 (80%)

13 (76.47%)

11 (68.75%)

 G3

24 [1] (15.38%)

7 (14.9%)

10 [1] (17.86%)

1 (5%)

3 (17.65%)

3 (18.75%)

 No grading provided^d

3 [1] (1.92%)

0 (0%)

2 [1] (3.57%)

1 (5%)

0 (0%)

0 (0%)

TNM-Staging

 cTNM-Staging

  cT1

19 (12.10%)

15 (31.91%)

2 (3.51%)

0 (0%)

1 (5.88%)

1 (6.25%)

  cT2

29 (18.47%)

11 (23.4%)

12 (21.05%)

4 (20%)

0 (0%)

2 (12.5%)

  cT3

32 (20.38%)

6 (14.63%)

12 (21.05%)

5 (25%)

5 (29.41%)

4 (25%)

  cT4

77 (49.04%)

15 (31.91%)

31 (54.39%)

11 (55%)

11 (22%)

9 (56.25%)

  cN0

52 (33.12%)

24 (51.06%)

10 (17.54%)

8 (40%)

4 (23.53%)

6 (37.5%)

  cN1

28 (17.83%)

12 (25.53%)

8 (14.04%)

2 (10%)

3 (17.65%)

3 (18.75%)

  cN2

55 (35.03%)

6 (12.77%)

31 (54.39%)

7 (35%)

5 (29.41%)

6 (37.5%)

  cN3

4 (2.54%)

0 (0%)

2 (3.51%)

0 (0%)

2 (11.76%)

0 (0%)

  cNX

18 (11.46%)

5 [42] (10.64%)

6 (10.53%)

3 (15%)

3 (17.65%)

1 (6.25%)

  cM0

148 (94.27%)

47 (100%)

53 (92.98%)

20 (100%)

13 (76.47%)

15 (93.75%)

  cM1

5 (3.19%)

0 (0%)

3 (5.26%)

0 (0%)

2 (11.76%)

0 (0%)

  cMX

4 (2.54%)

0 (0%)

1 (1.75%)

0 (0%)

2 (11.76%)

1 (6.25%)

 pTNM-Staging^e

47 [110] (29.94%)

  pT

39 [118] (24.84%)

39 [8] (83%)

   pT0

1 [118] (2.56%)

1 [8] (2.56%)

   pT1

9 [118] (23.08%)

9 [8] (23.08%)

   pT2

13 [118] (33.33%)

13 [8] (33.33%)

   pT3

6 [118] (15.38%)

6 [8] (15.38%)

   pT4

10 [118] (25.64%)

10 [8] (25.64%)

   pTX

0 [118] (0%)

0 [8] (0%)

   pTis

0 [118] (0%)

0 [8] (0%)

  pN

39 [118] (24.84%)

39 [8] (83%)

   pN0

25 [118] (64.01%)

25 [8] (64.01%)

   pN1

6 [118] (15.38%)

6 [8] (15.38%)

   pN2

6 [118] (15.38%)

6 [8] (15.38%)

   pN3

2 [118] (5.12%)

2 [8] (5.12%)

   pNX

0 [118] (0%)

0 [8] (0%)

  pM

39 [118] (24.84%)

39 [8] (83%)

   pM0

39 [118] (100%)

39 [8] (100%)

   pM1

0 [118] (0%)

0 [8] (0%)

  L

30 [127] (19.11%)

30 [17] (63.83%)

   L0

24 [127] (80%)

24 [17] (80%)

   L1

6 [127] (20%)

6 [17] (20%)

  V

31 [126] (19.75%)

31 [16] (65.96%)

   V0

28 [126] (90.32%)

28 [16] (90.32%)

   V1

3 [126] (9.68%)

3 [16] (9.68%)

  Pn

30 [127] (19.1%)

30 [17] (63.83%)

   Pn0

27 [127] (90%)

27 [17] (90%)

   Pn1

3 [127] (10%)

3 [17] (10%)

 Resection margin

32 [125] (20.38%)

32 [15] (68.1%)

  R0

28 [125] (87.5%)

28 [15] (87.5%)

  R1

3 [125] (9.4%)

3 [15] (9.4%)

  RX

1 [125] (3.1%)

1 [15] (3.1%)

Local histologic follow-up

80 [77] (50.96%)

28 [19] (59.57%)

39 [18] (68.42%)

8 [12] (40%)

0 [17] (0%)

5 [11] (31.25%)

 Local relapse histologically confirmed

18 [77] (22.5%)

9 [19] (32.14%)

4 [18] (10.26%)

2 [12] (25%%)

0 [17] (0%)

3 [11] (60%)

 Local relapse histologically excluded

62 [77] (77.5%)

19 [19] (67.86%)

35 [18] (89.74%)

6 [12] (75%)

0 [17] (0%)

2 [11] (40%)